High antimüllerian hormone levels are associated with preterm delivery in patients with polycystic ovary syndrome

High levels of antimullerian hormone (>75th percentile) are associated with preterm delivery in patients with polycystic ovary syndrome.

Like Comment
Related Content

Volume 113, Issue 2, Pages 444–452.e1

Authors:

Kai-Lun Hu, M.D., Fen-Ting Liu, M.D., Huiyu Xu, M.D., Rong Li, M.D., Ph.D., Jie Qiao, M.D., Ph.D.

Abstract:

Context

Antimüllerian hormone (AMH) levels are higher in patients with polycystic ovary syndrome (PCOS). Accumulating evidence indicates that AMH has an impact on the physiology of the female reproductive system.

Objective

To investigate the association of AMH levels with the risk of preterm delivery in PCOS patients.

Design

Retrospective cohort study.

Setting

Academic fertility center.

Patients

Women who underwent in vitro fertilization between January 2017 and July 2018 (25,165 cycles).

Interventions

None.

Main Outcome Measures

The primary outcome was preterm delivery.

Results

Serum AMH levels were not different between the term delivery and preterm delivery groups in the entire cohort (3.8 vs. 4.1 ng/mL, P>.05). In patients diagnosed with PCOS, those with preterm delivery had higher AMH levels than were found in patients with term delivery (9.3 vs. 6.9 ng/mL, P<.01). Preterm deliveries predominated in PCOS patients with AMH levels above the 75th percentile (9.75 ng/mL) (adjusted P<.0001, adjusted odds ratio [OR] 4.0, 95% confidence interval [CI] 1.94, 8.08)) and frozen−thawed embryo transfer (FET) patients with AMH levels higher than the 90th percentile (10.10 ng/mL) (adjusted P<.05, adjusted OR 2.0, 95% CI 1.16, 3.36).

Conclusion

Serum AMH levels higher than 75th percentile were associated with an increased risk of preterm delivery in patients with PCOS, and serum AMH levels higher than the 90th percentile were associated with an increased risk of preterm delivery in FET patients.


Read the full text here.

Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.